ISSUE – Nov. 13 | Why an investor at Andreessen Horowitz thinks software is the future of healthcare

It’s not exactly surprising that a partner of a venture capital firm with a tagline that “software is eating the world” thinks the same could be said for the drug industry. Vijay Pande, a general partner at Andreessen Horowitz, runs the firm’s bio fund. So far, the fund’s made investments in companies including Freenome, which is developing a blood test that screens for the earliest signs of cancer, and Q, a startup that wants to quantify the human physiology. [ Business Insider ]